The Endocrine Tumor Summit 2008: Appraising Therapeutic Approaches for Acromegaly and Carcinoid Syndrome

The Endocrine Tumor Summit 2008: Appraising Therapeutic Approaches for Acromegaly and Carcinoid Syndrome

DSpace/Manakin Repository

The Endocrine Tumor Summit 2008: Appraising Therapeutic Approaches for Acromegaly and Carcinoid Syndrome

dc.contributor.author	Melmed, Shlomo
dc.contributor.author	Clemmons, David R.
dc.contributor.author	Colao, Annamaria
dc.contributor.author	Cunningham, Regina S.
dc.contributor.author	Molitch, Mark E.
dc.contributor.author	Vinik, Aaron I.
dc.contributor.author	Adelman, Daphne T.
dc.contributor.author	Liebert, Karen J. P.
dc.contributor.author	Klibanski, Anne
dc.date.accessioned	2012-02-04T22:31:50Z
dc.date.issued	2009
dc.identifier.citation	Klibanski, Anne, Shlomo Melmed, David R. Clemmons, Annamaria Colao, Regina S. Cunningham, Mark E. Molitch, Aaron I. Vinik, Daphne T. Adelman, and Karen J. P. Liebert. 2009. The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. Pituitary 13(3): 266-286.	en_US
dc.identifier.issn	1386-341X	en_US
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8123171
dc.description.abstract	The Endocrine Tumor Summit convened in December 2008 to address 6 statements prepared by panel members that reflect important questions in the treatment of acromegaly and carcinoid syndrome. Data pertinent to each of the statements were identified through review of pertinent literature by one of the 9-member panel, enabling a critical evaluation of the statements and the evidence supporting or refuting them. Three statements addressed the validity of serum growth hormone (GH) and insulin-like growth factor-I (IGF-I) concentrations as indicators or predictors of disease in acromegaly. Statements regarding the effects of preoperative somatostatin analog use on pituitary surgical outcomes, their effects on hormone and symptom control in carcinoid syndrome, and the efficacy of extended dosing intervals were reviewed. Panel opinions, based on the level of available scientific evidence, were polled. Finally, their views were compared with those of surveyed community-based endocrinologists and neurosurgeons.	en_US
dc.language.iso	en_US	en_US
dc.publisher	Springer US	en_US
dc.relation.isversionof	doi:10.1007/s11102-009-0210-2	en_US
dc.relation.hasversion	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913001/pdf/	en_US
dash.license	LAA
dc.subject	acromegaly	en_US
dc.subject	Carcinoid syndrome	en_US
dc.subject	neuroendocrine tumor	en_US
dc.subject	NET	en_US
dc.subject	somatostatin analogs	en_US
dc.subject	somatostatin analogues	en_US
dc.subject	lanreotide	en_US
dc.subject	octreotide	en_US
dc.subject	insulin-like growth factor-I	en_US
dc.subject	IGF-I	en_US
dc.subject	growth hormone	en_US
dc.subject	GH	en_US
dc.title	The Endocrine Tumor Summit 2008: Appraising Therapeutic Approaches for Acromegaly and Carcinoid Syndrome	en_US
dc.type	Journal Article	en_US
dc.description.version	Version of Record	en_US
dc.relation.journal	Pituitary	en_US
dash.depositing.author	Klibanski, Anne
dc.date.available	2012-02-04T22:31:50Z
dash.affiliation.other	HMS^Medicine-Massachusetts General Hospital	en_US